nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—Regorafenib—NTRK1—periodontitis	0.0267	1	CrCbGaD
Sorafenib—CSF1R—periosteum—periodontitis	0.0224	0.0597	CbGeAlD
Sorafenib—TIE1—endothelium—periodontitis	0.0156	0.0415	CbGeAlD
Sorafenib—FLT4—endothelium—periodontitis	0.0129	0.0343	CbGeAlD
Sorafenib—FLT1—endothelium—periodontitis	0.01	0.0267	CbGeAlD
Sorafenib—CDK7—connective tissue—periodontitis	0.00931	0.0248	CbGeAlD
Sorafenib—KDR—endothelium—periodontitis	0.00845	0.0225	CbGeAlD
Sorafenib—HIPK3—connective tissue—periodontitis	0.00788	0.021	CbGeAlD
Sorafenib—EPHX2—parotid gland—periodontitis	0.00766	0.0204	CbGeAlD
Sorafenib—KIT—endothelium—periodontitis	0.00749	0.02	CbGeAlD
Sorafenib—RET—neck—periodontitis	0.00749	0.02	CbGeAlD
Sorafenib—FGFR1—trigeminal ganglion—periodontitis	0.00723	0.0193	CbGeAlD
Sorafenib—TIE1—epithelium—periodontitis	0.00699	0.0186	CbGeAlD
Sorafenib—MAP3K7—trigeminal ganglion—periodontitis	0.00684	0.0182	CbGeAlD
Sorafenib—FLT3—connective tissue—periodontitis	0.0067	0.0179	CbGeAlD
Sorafenib—MKNK2—trigeminal ganglion—periodontitis	0.00663	0.0177	CbGeAlD
Sorafenib—FLT1—neck—periodontitis	0.0066	0.0176	CbGeAlD
Sorafenib—RAF1—neck—periodontitis	0.00656	0.0175	CbGeAlD
Sorafenib—MKNK1—trigeminal ganglion—periodontitis	0.00655	0.0175	CbGeAlD
Sorafenib—RET—trigeminal ganglion—periodontitis	0.00647	0.0172	CbGeAlD
Sorafenib—MAP3K7—parotid gland—periodontitis	0.00645	0.0172	CbGeAlD
Sorafenib—MKNK2—parotid gland—periodontitis	0.00626	0.0167	CbGeAlD
Sorafenib—RALBP1—trigeminal ganglion—periodontitis	0.00599	0.016	CbGeAlD
Sorafenib—KIT—mouth—periodontitis	0.00578	0.0154	CbGeAlD
Sorafenib—FLT4—epithelium—periodontitis	0.00577	0.0154	CbGeAlD
Sorafenib—FLT1—trigeminal ganglion—periodontitis	0.0057	0.0152	CbGeAlD
Sorafenib—RAF1—trigeminal ganglion—periodontitis	0.00566	0.0151	CbGeAlD
Sorafenib—RALBP1—parotid gland—periodontitis	0.00565	0.0151	CbGeAlD
Sorafenib—EPHB6—trigeminal ganglion—periodontitis	0.00563	0.015	CbGeAlD
Sorafenib—KDR—neck—periodontitis	0.00558	0.0149	CbGeAlD
Sorafenib—MKNK2—connective tissue—periodontitis	0.00551	0.0147	CbGeAlD
Sorafenib—STK10—trigeminal ganglion—periodontitis	0.00539	0.0144	CbGeAlD
Sorafenib—FLT1—parotid gland—periodontitis	0.00537	0.0143	CbGeAlD
Sorafenib—RET—connective tissue—periodontitis	0.00537	0.0143	CbGeAlD
Sorafenib—RAF1—parotid gland—periodontitis	0.00534	0.0142	CbGeAlD
Sorafenib—EPHB6—parotid gland—periodontitis	0.00531	0.0142	CbGeAlD
Sorafenib—MKNK2—epithelium—periodontitis	0.00523	0.0139	CbGeAlD
Sorafenib—RET—epithelium—periodontitis	0.0051	0.0136	CbGeAlD
Sorafenib—KIT—neck—periodontitis	0.00494	0.0132	CbGeAlD
Sorafenib—PDGFRB—neck—periodontitis	0.00483	0.0129	CbGeAlD
Sorafenib—KDR—trigeminal ganglion—periodontitis	0.00482	0.0128	CbGeAlD
Sorafenib—MAP2K5—trigeminal ganglion—periodontitis	0.00482	0.0128	CbGeAlD
Sorafenib—FLT1—connective tissue—periodontitis	0.00473	0.0126	CbGeAlD
Sorafenib—RAF1—connective tissue—periodontitis	0.0047	0.0125	CbGeAlD
Sorafenib—CSF1R—trigeminal ganglion—periodontitis	0.0047	0.0125	CbGeAlD
Sorafenib—MAP2K5—parotid gland—periodontitis	0.00454	0.0121	CbGeAlD
Sorafenib—KDR—parotid gland—periodontitis	0.00454	0.0121	CbGeAlD
Sorafenib—FLT1—epithelium—periodontitis	0.00449	0.012	CbGeAlD
Sorafenib—RAF1—epithelium—periodontitis	0.00446	0.0119	CbGeAlD
Sorafenib—PDGFRA—connective tissue—periodontitis	0.00443	0.0118	CbGeAlD
Sorafenib—KIT—trigeminal ganglion—periodontitis	0.00427	0.0114	CbGeAlD
Sorafenib—PDGFRB—trigeminal ganglion—periodontitis	0.00417	0.0111	CbGeAlD
Sorafenib—KIT—parotid gland—periodontitis	0.00403	0.0107	CbGeAlD
Sorafenib—KDR—connective tissue—periodontitis	0.004	0.0107	CbGeAlD
Sorafenib—PDGFRB—parotid gland—periodontitis	0.00393	0.0105	CbGeAlD
Sorafenib—CSF1R—connective tissue—periodontitis	0.0039	0.0104	CbGeAlD
Sorafenib—KDR—epithelium—periodontitis	0.0038	0.0101	CbGeAlD
Sorafenib—KIT—connective tissue—periodontitis	0.00354	0.00944	CbGeAlD
Sorafenib—PDGFRB—connective tissue—periodontitis	0.00346	0.00922	CbGeAlD
Sorafenib—KIT—epithelium—periodontitis	0.00336	0.00897	CbGeAlD
Sorafenib—PDGFRB—epithelium—periodontitis	0.00328	0.00876	CbGeAlD
Sorafenib—ABCG2—trigeminal ganglion—periodontitis	0.00234	0.00625	CbGeAlD
Sorafenib—ABCG2—parotid gland—periodontitis	0.00221	0.00589	CbGeAlD
Sorafenib—ABCB1—trigeminal ganglion—periodontitis	0.00116	0.00308	CbGeAlD
Sorafenib—ABCB1—epithelium—periodontitis	0.00091	0.00243	CbGeAlD
Sorafenib—KIT—Disease—NOS2—periodontitis	5.74e-05	9.6e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—periodontitis	5.72e-05	9.55e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—IL6—periodontitis	5.7e-05	9.53e-05	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TGFB1—periodontitis	5.7e-05	9.53e-05	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—TNF—periodontitis	5.7e-05	9.52e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NTRK1—periodontitis	5.7e-05	9.52e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NTRK1—periodontitis	5.68e-05	9.5e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TGFB1—periodontitis	5.65e-05	9.44e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—FGF2—periodontitis	5.62e-05	9.4e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ACP5—periodontitis	5.62e-05	9.4e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCR2—periodontitis	5.6e-05	9.36e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—MMP9—periodontitis	5.59e-05	9.34e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP3—periodontitis	5.58e-05	9.33e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP3—periodontitis	5.58e-05	9.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—TLR4—periodontitis	5.58e-05	9.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ADRB1—periodontitis	5.57e-05	9.31e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CXCL8—periodontitis	5.56e-05	9.29e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TGFB1—periodontitis	5.56e-05	9.29e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NOS2—periodontitis	5.45e-05	9.11e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NOS2—periodontitis	5.44e-05	9.09e-05	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—IL6—periodontitis	5.37e-05	8.98e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP3—periodontitis	5.3e-05	8.85e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IFNG—periodontitis	5.29e-05	8.85e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP3—periodontitis	5.28e-05	8.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CRP—periodontitis	5.19e-05	8.67e-05	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—IL6—periodontitis	5.16e-05	8.63e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—FGF2—periodontitis	5.14e-05	8.6e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC52A3—periodontitis	5.12e-05	8.56e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NTRK1—periodontitis	5.12e-05	8.56e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—FGF2—periodontitis	5.07e-05	8.48e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—FGF2—periodontitis	5.07e-05	8.48e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GGT1—periodontitis	5.04e-05	8.42e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MMP9—periodontitis	5.03e-05	8.41e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—periodontitis	5.03e-05	8.4e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ACP5—periodontitis	5.02e-05	8.39e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CCL2—periodontitis	5e-05	8.35e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GGT1—periodontitis	5e-05	8.35e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—TLR4—periodontitis	4.97e-05	8.31e-05	CbGpPWpGaD
Sorafenib—MKNK1—Disease—IL6—periodontitis	4.95e-05	8.28e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—periodontitis	4.93e-05	8.24e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NOS2—periodontitis	4.9e-05	8.19e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ACP5—periodontitis	4.9e-05	8.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TGFB1—periodontitis	4.89e-05	8.17e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—periodontitis	4.88e-05	8.16e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NTRK1—periodontitis	4.88e-05	8.16e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR2—periodontitis	4.83e-05	8.08e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—FGF2—periodontitis	4.81e-05	8.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ADRB1—periodontitis	4.81e-05	8.04e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CCL2—periodontitis	4.8e-05	8.03e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—FGF2—periodontitis	4.8e-05	8.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TGFB1—periodontitis	4.79e-05	8.01e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IFNG—periodontitis	4.77e-05	7.98e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IFNG—periodontitis	4.77e-05	7.98e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP3—periodontitis	4.76e-05	7.95e-05	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—IL6—periodontitis	4.75e-05	7.93e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL1B—periodontitis	4.72e-05	7.89e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—FGF2—periodontitis	4.68e-05	7.83e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CCL2—periodontitis	4.68e-05	7.82e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CCL2—periodontitis	4.67e-05	7.8e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—PTGS2—periodontitis	4.64e-05	7.76e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—TGFB1—periodontitis	4.63e-05	7.74e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ACP5—periodontitis	4.62e-05	7.72e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TGFB1—periodontitis	4.6e-05	7.7e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—periodontitis	4.6e-05	7.69e-05	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—IL6—periodontitis	4.6e-05	7.69e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ACP5—periodontitis	4.58e-05	7.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TNF—periodontitis	4.56e-05	7.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NTRK1—periodontitis	4.56e-05	7.63e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP3—periodontitis	4.54e-05	7.59e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IFNG—periodontitis	4.53e-05	7.57e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IFNG—periodontitis	4.52e-05	7.55e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—periodontitis	4.49e-05	7.5e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—FGF2—periodontitis	4.44e-05	7.43e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—FGF2—periodontitis	4.43e-05	7.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS2—periodontitis	4.37e-05	7.3e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—CXCL8—periodontitis	4.35e-05	7.27e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FGF2—periodontitis	4.34e-05	7.25e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—FGF2—periodontitis	4.33e-05	7.23e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—IL6—periodontitis	4.28e-05	7.15e-05	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—IL6—periodontitis	4.28e-05	7.15e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL1B—periodontitis	4.26e-05	7.11e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL1B—periodontitis	4.26e-05	7.11e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IL6—periodontitis	4.26e-05	7.11e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PPARA—periodontitis	4.25e-05	7.11e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PPARA—periodontitis	4.25e-05	7.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP3—periodontitis	4.24e-05	7.09e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FGF2—periodontitis	4.23e-05	7.07e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PTGS2—periodontitis	4.22e-05	7.06e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IL6—periodontitis	4.19e-05	7e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—PPARA—periodontitis	4.16e-05	6.96e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TGFB1—periodontitis	4.14e-05	6.93e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—periodontitis	4.09e-05	6.84e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IFNG—periodontitis	4.07e-05	6.8e-05	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—IL6—periodontitis	4.06e-05	6.79e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—IL6—periodontitis	4.05e-05	6.77e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL1B—periodontitis	4.04e-05	6.75e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CCL2—periodontitis	4.03e-05	6.74e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1B—periodontitis	4.03e-05	6.73e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCL2—periodontitis	4.02e-05	6.73e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PTGS2—periodontitis	4.01e-05	6.7e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PTGS2—periodontitis	4e-05	6.68e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FGF2—periodontitis	3.99e-05	6.68e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCL2—periodontitis	3.99e-05	6.66e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CXCL8—periodontitis	3.95e-05	6.6e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NTRK1—periodontitis	3.94e-05	6.58e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ACP5—periodontitis	3.91e-05	6.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FGF2—periodontitis	3.86e-05	6.44e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CXCL8—periodontitis	3.8e-05	6.35e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CXCL8—periodontitis	3.7e-05	6.18e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GGT1—periodontitis	3.69e-05	6.17e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CXCL8—periodontitis	3.69e-05	6.17e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—periodontitis	3.68e-05	6.16e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP3—periodontitis	3.66e-05	6.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—periodontitis	3.65e-05	6.1e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGF2—periodontitis	3.64e-05	6.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1B—periodontitis	3.63e-05	6.07e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCL2—periodontitis	3.63e-05	6.06e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCL2—periodontitis	3.63e-05	6.06e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFNG—periodontitis	3.63e-05	6.06e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GGT1—periodontitis	3.61e-05	6.04e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PPARA—periodontitis	3.61e-05	6.03e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGF2—periodontitis	3.6e-05	6.02e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTGS2—periodontitis	3.6e-05	6.02e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PPARA—periodontitis	3.58e-05	5.98e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGF2—periodontitis	3.56e-05	5.95e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CXCL8—periodontitis	3.51e-05	5.86e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—periodontitis	3.5e-05	5.84e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—periodontitis	3.49e-05	5.83e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—periodontitis	3.47e-05	5.8e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCL2—periodontitis	3.44e-05	5.76e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCL2—periodontitis	3.43e-05	5.74e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—periodontitis	3.43e-05	5.74e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—periodontitis	3.35e-05	5.61e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—periodontitis	3.35e-05	5.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGF2—periodontitis	3.28e-05	5.48e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGF2—periodontitis	3.28e-05	5.48e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—periodontitis	3.27e-05	5.46e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—periodontitis	3.25e-05	5.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—periodontitis	3.24e-05	5.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—periodontitis	3.21e-05	5.37e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CXCL8—periodontitis	3.19e-05	5.33e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CXCL8—periodontitis	3.18e-05	5.32e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CXCL8—periodontitis	3.15e-05	5.27e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GGT1—periodontitis	3.13e-05	5.23e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—periodontitis	3.12e-05	5.22e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGF2—periodontitis	3.11e-05	5.2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGF2—periodontitis	3.1e-05	5.19e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL2—periodontitis	3.09e-05	5.17e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—periodontitis	3.05e-05	5.1e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ACP5—periodontitis	3.02e-05	5.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL2—periodontitis	2.95e-05	4.93e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—periodontitis	2.92e-05	4.88e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—periodontitis	2.9e-05	4.84e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—periodontitis	2.89e-05	4.83e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—periodontitis	2.88e-05	4.81e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL8—periodontitis	2.87e-05	4.8e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL8—periodontitis	2.87e-05	4.8e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—periodontitis	2.85e-05	4.76e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—periodontitis	2.83e-05	4.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGF2—periodontitis	2.8e-05	4.67e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GGT1—periodontitis	2.79e-05	4.67e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—periodontitis	2.76e-05	4.62e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—periodontitis	2.76e-05	4.62e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—periodontitis	2.76e-05	4.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL2—periodontitis	2.76e-05	4.61e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—periodontitis	2.76e-05	4.61e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GGT1—periodontitis	2.72e-05	4.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL8—periodontitis	2.72e-05	4.55e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL8—periodontitis	2.72e-05	4.54e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGF2—periodontitis	2.67e-05	4.46e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—periodontitis	2.66e-05	4.45e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARA—periodontitis	2.64e-05	4.42e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—periodontitis	2.6e-05	4.35e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—periodontitis	2.59e-05	4.34e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—periodontitis	2.59e-05	4.34e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARA—periodontitis	2.58e-05	4.32e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GGT1—periodontitis	2.57e-05	4.29e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GGT1—periodontitis	2.55e-05	4.25e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—periodontitis	2.53e-05	4.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGF2—periodontitis	2.49e-05	4.17e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—periodontitis	2.49e-05	4.17e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—periodontitis	2.49e-05	4.17e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—periodontitis	2.46e-05	4.12e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—periodontitis	2.46e-05	4.11e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL8—periodontitis	2.45e-05	4.09e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—periodontitis	2.38e-05	3.98e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—periodontitis	2.37e-05	3.96e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—periodontitis	2.37e-05	3.95e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—periodontitis	2.36e-05	3.94e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—periodontitis	2.35e-05	3.93e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—periodontitis	2.35e-05	3.92e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL8—periodontitis	2.33e-05	3.9e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—periodontitis	2.32e-05	3.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—periodontitis	2.32e-05	3.88e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—periodontitis	2.3e-05	3.85e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—periodontitis	2.27e-05	3.8e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARA—periodontitis	2.24e-05	3.74e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—periodontitis	2.22e-05	3.71e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—periodontitis	2.21e-05	3.7e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—periodontitis	2.18e-05	3.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—periodontitis	2.18e-05	3.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—periodontitis	2.18e-05	3.64e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GGT1—periodontitis	2.18e-05	3.64e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF2—periodontitis	2.15e-05	3.6e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—periodontitis	2.14e-05	3.57e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—periodontitis	2.14e-05	3.57e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—periodontitis	2.13e-05	3.56e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—periodontitis	2.13e-05	3.55e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—periodontitis	2.11e-05	3.53e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—periodontitis	2.08e-05	3.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—periodontitis	2.07e-05	3.47e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—periodontitis	2.03e-05	3.39e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—periodontitis	2.02e-05	3.38e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARA—periodontitis	2e-05	3.34e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—periodontitis	1.97e-05	3.3e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—periodontitis	1.96e-05	3.28e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARA—periodontitis	1.95e-05	3.26e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—periodontitis	1.89e-05	3.17e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—periodontitis	1.88e-05	3.15e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARA—periodontitis	1.84e-05	3.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—periodontitis	1.82e-05	3.05e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARA—periodontitis	1.82e-05	3.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—periodontitis	1.79e-05	2.99e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—periodontitis	1.79e-05	2.99e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—periodontitis	1.77e-05	2.96e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—periodontitis	1.75e-05	2.92e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—periodontitis	1.74e-05	2.91e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—periodontitis	1.72e-05	2.87e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—periodontitis	1.7e-05	2.85e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—periodontitis	1.68e-05	2.81e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT1—periodontitis	1.68e-05	2.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—periodontitis	1.63e-05	2.72e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—periodontitis	1.61e-05	2.69e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—periodontitis	1.61e-05	2.69e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARA—periodontitis	1.56e-05	2.6e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—periodontitis	1.53e-05	2.56e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—periodontitis	1.53e-05	2.55e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—periodontitis	1.46e-05	2.43e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—periodontitis	1.4e-05	2.35e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—periodontitis	1.37e-05	2.3e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—periodontitis	1.31e-05	2.19e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—periodontitis	1.3e-05	2.17e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—periodontitis	1.27e-05	2.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—periodontitis	1.22e-05	2.05e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARA—periodontitis	1.2e-05	2.01e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—periodontitis	1.19e-05	2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—periodontitis	1.18e-05	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—periodontitis	1.06e-05	1.77e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—periodontitis	1.01e-05	1.69e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—periodontitis	7.81e-06	1.31e-05	CbGpPWpGaD
